Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.24 +0.71 (+1.07%)
Official Closing Price Updated: 7:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,733,654
Open 66.73
Bid (Size) 66.55 (1)
Ask (Size) 67.28 (4)
Prev. Close 66.53
Today's Range 66.24 - 67.38
52wk Range 65.28 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 2.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
 
Via Benzinga
Wall Street Is Bullish on GE HealthCare as It Invests in AI
The stand-alone company that spun off from GE in January is off to a good start. 
Via The Motley Fool

Performance

YTD
-6.95%
-6.95%
1 Month
-5.44%
-5.44%
3 Month
-8.09%
-8.09%
6 Month
-4.20%
-4.20%
1 Year
-5.36%
-5.36%

More News

Read More
4 Top Value Stock ETFs for Long-Term Wealth Building
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
Via The Motley Fool
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
This Big Pharma Stock Is a Clear Buy
Via The Motley Fool
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows
Via The Motley Fool
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
From Bristol Myers Squibb
Via Business Wire
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023
From Bristol Myers Squibb
Via Business Wire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in Cowen’s 43rd Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
7 Dividend Stocks to Buy During a Market Downturn
Via InvestorPlace
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology
From Bristol Myers Squibb
Via Business Wire
Why Nektar Therapeutics Stock Is Plunging Today
Via Benzinga
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
Via FinancialNewsMedia
This Recession-Proof Company Has a Best-in-Class Dividend
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.